ANTIBODIES TO POLYPHOSPHATE DECREASE CLOT FORMATION, DECREASE INFLAMMATION, AND IMPROVE SURVIVAL

摘要

Hypercoagulable and hyperinflammatory responses can lead to a variety of diseases including but not limited to disseminated intravascular coagulation in sepsis, consumptive coagulopathy in trauma, thrombosis in the postsurgical setting, acute respiratory distress syndrome in lung, and other diseases or conditions. Polyphosphate is accumulated by many infectious microorganisms and may be released by damaged infectious microorganisms. In addition, polyphosphate is found in many organs and is released from activated platelets and mast cells. Polyphosphates activate the intrinsic pathway of coagulation that also induces inflammation. Hypercoagulable and hyperinflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death, which occur in many pathological conditions. As such, polyphosphates can be targeted pharmacologically by inhibitors, such as anti-polyphosphate antibodies, as well as used as biomarkers for diagnosis, prognosis, and treatment response indicators that may be used to provide guidance for alterations in treatment plans.